The global IVD regulatory landscape is undergoing its most significant transformation in a generation. The EU IVDR — which replaced the IVD Directive in May 2022 — has dramatically increased the evidence requirements for most IVD products, reclassified thousands of tests to higher risk classes, and imposed new obligations on manufacturers, notified bodies, and distributors. The FDA's LDT rule — finalized in May 2024 — has brought laboratory-developed tests under FDA oversight for the first time, creating compliance requirements for the estimated 12,000+ LDTs offered by U.S. clinical laboratories. Simultaneously, China's NMPA is tightening IVD import requirements, mandating local clinical studies for most foreign products. Understanding the regulatory pathway — from product classification and predicate identification to clinical performance studies and post-market surveillance — is essential for every IVD product strategy.
Topics Covered
• IVD Regulatory Landscape Overview — FDA, EU IVDR, NMPA, and Global Frameworks
• FDA 510(k) Pathway — Predicate Strategy, Special Controls, and De Novo Classification
• FDA PMA Pathway — Requirements, Clinical Study Design, and High-Risk IVD Strategy
• FDA LDT Rule — Scope, Timeline, Compliance Requirements, and Market Impact
• EU IVDR — Classification Rules, Notified Body Requirements, and Transition Status
• EU IVDR Performance Studies — PMPF, Scientific Validity, and Clinical Evidence Requirements
• China NMPA — Registration Classes, Local Clinical Study Requirements, and Timeline
• Japan PMDA, Australia TGA, and Other Key Market Regulatory Strategies
• Companion Diagnostic Co-Development — FDA/EMA Regulatory Alignment with Drug Partners
• Global Submission Strategy — Harmonization, Work-Sharing, and Market Entry Sequencing
'
Table of Contents
1. Executive Summary
- Key findings and strategic implications
- Most significant regulatory developments 2024-2025
- Strategic recommendations
2. Global IVD Regulatory Landscape
- Key regulatory frameworks — FDA, EU IVDR, NMPA, and global
- Regulatory complexity as competitive driver
- Compliance cost analysis by company size and segment
3. FDA 510(k) Pathway
- Predicate identification and substantial equivalence strategy
- Special controls and performance testing requirements
- De Novo classification pathway for novel devices
4. FDA PMA Pathway
- Pre-market approval requirements and process
- Clinical study design for high-risk IVD
- Modular PMA and panel review strategy
5. FDA LDT Rule
- Scope and classification of affected LDTs
- Compliance timeline and enforcement discretion
- Market implications for Quest, LabCorp, and hospital laboratories
6. EU IVDR
- Classification rules and performance study requirements
- Notified body certification process and capacity
- Transition timeline and product certification status
7. China NMPA
- Registration classes and technical requirements
- Local clinical study design and execution
- Import licensing and market access strategy
8. Japan PMDA, Australia TGA, and Other Key Markets
- PMDA regulatory pathway and NHI linkage
- TGA classification and regulatory requirements
- Emerging market regulatory harmonization
9. Companion Diagnostic Co-Development
- FDA and EMA CDx regulatory alignment with drug partners
- Simultaneous CDx and drug submission strategy
- Post-approval CDx label management
10. Global Submission Strategy
- Multi-market submission planning and sequencing
- Regulatory work-sharing programs
- Global regulatory resource planning
11. Appendix
- Research methodology
- Abbreviations and definitions
- List of tables and figures
List of Tables
Table 1. FDA 510(k) Submission Requirements — Analytical and Clinical Performance Standards
Table 2. FDA PMA Requirements — Clinical Study Design and Evidence Package
Table 3. FDA LDT Rule — Scope, Timeline, and Affected Laboratory Tests 2025
Table 4. EU IVDR Classification Rules — Impact on IVD Product Portfolio
Table 5. EU IVDR Performance Study Requirements — PMPF and Scientific Validity
Table 6. China NMPA Registration Requirements — By Device Class and Product Category
Table 7. Japan PMDA and Australia TGA — Regulatory Requirements Summary
Table 8. Companion Diagnostic Co-Development — Regulatory Alignment Framework
Table 9. Global Submission Strategy — Market Entry Sequencing by Regulatory Complexity
Table 10. Key Risks and Mitigation Strategies
Abbott Diagnostics
Bio-Rad Laboratories
bioMérieux
Danaher (Beckman Coulter, Cepheid, Radiometer)
DiaSorin
Hologic
QuidelOrtho
Roche Diagnostics
Siemens Healthineers
Sysmex
